Athos Therapeutics Announces their Corporate Circle Membership to the Crohn's & Colitis Foundation and Participation in the BD Innovate Conference

Athos Therapeutics宣布他们的企业圈子成为克罗恩和结肠炎基金会的成员,并参加BD创新会议

2021-10-14 02:00:11 BioSpace

本文共1492个字,阅读需4分钟

Athos Therapeutics, Inc., a late preclinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with autoimmune diseases and cancer, today announced their Corporate Circle Membership to the Crohn's & Colitis Foundation and participation in the IBD Innovate conference. At the IBD INNOVATE: Product Development for Crohn's & Colitis™ conference (https://www.crohnscolitisfoundation.org/ibd-innovate) Athos will be presenting exciting new data regarding its innovative platform to develop precision medicine therapeutics for IBD patients. Athos uses a systems biology approach to characterize the heterogeneity of IBD pathobiology at the molecular level. The Company is developing precision therapeutics by the stratification of IBD patients into specific molecular subtypes. "Athos is committed to develop first-in-class IBD therapeutics that will be in stark contrast to currently prescribed medications for IBD that are limited by low efficacy, dangerous side effects, and a non-specific approach that fails to address multiple IBD patient subtypes," said Dimitrios Iliopoulos, PhD, MBA, Chief Executive Officer of Athos. "Our membership with the Crohn's & Colitis Foundation will enhance our collaborative efforts with the foundation, FDA, and other pharmaceutical companies to develop IBD precision therapeutics. We are honored to be a member of CCF's corporate circle." "The Crohn's & Colitis Foundation represents the premiere non-profit organization dedicated to finding cures for Crohn's disease and ulcerative colitis," said Allan J. Pantuck, MD, MS, Chairman and Chief Medical Officer of Athos. "We look forward to supporting its mission and working closely with the Crohn's & Colitis Foundation to help find new treatments and improve the quality of life of those affected by these diseases." John Mize, Senior Vice President of Business Development for the Crohn's & Colitis Foundation added, "The Foundation is committed to finding new and better treatments for IBD and improving patient quality of life. We are grateful to Athos for supporting our mission and appreciate the impact Athos is making on the IBD community." About Athos Therapeutics Athos Therapeutics Inc. is a late-stage preclinical biotech company developing small molecule therapeutics for autoimmune diseases using a highly innovative chemistry and computational process. The co-founders of Athos include a co-founder of Kite Pharma (acquired for $12B), the medicinal chemist behind two multi-billion dollar FDA-approved drugs (Xtandi & Erleada), and the discoverer of the miR-124 drug target, currently in a Phase III IBD trial. Athos identifies novel drug targets (hubs) by integrating clinical and molecular datasets into disease interactomes and matches them to its small molecule computational chemistry platform. ATH-63, the Company's lead drug compound, is moving into a Phase Ia human clinical trials for patients with Ulcerative Colitis and Crohn's Disease Q12022. Pipeline programs include lupus and multiple cancers. About the Crohn's & Colitis Foundation The Crohn's & Colitis Foundation is the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD). The Foundation's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life for the millions of Americans living with IBD. Our work is dramatically accelerating the research process; we also provide extensive educational resources for patients and their families, medical professionals, and the public. For more information, visit http://www.crohnscolitisfoundation.org, call 888-694-8872, or email info@crohnscolitisfoundation.org. multimedia:https://www.prnewswire.com/news-releases/athos-therapeutics-announces-their-corporate-circle-membership-to-the-crohns--colitis-foundation-and-participation-in-the-ibd-innovate-conference-301399394.html
Athos Therapeutics,Inc.是一家为自身免疫性疾病和癌症患者开发一流精准疗法的晚期临床前阶段生物技术公司,今天宣布他们的企业圈子成为克罗恩&结肠炎基金会的成员,并参加IBD创新会议。 在IBD创新:克罗恩与结肠炎产品开发™会议(https://www.crohnscolitisfoundation.org/ibd-innovate)上,Athos将展示关于其创新平台的令人兴奋的新数据,以开发针对IBD患者的精准医学治疗。 Athos使用系统生物学方法在分子水平上描述IBD病理生物学的异质性。该公司正在通过将IBD患者分层为特定的分子亚型来开发精准治疗方法。 Athos首席执行官、MBA博士Dimitrios Iliopoulos说:“Athos致力于开发一流的IBD疗法,与目前针对IBD的处方药物形成鲜明对比,这些药物受到疗效低、危险副作用和非特异性方法的限制,无法解决多种IBD患者亚型。”“我们成为克罗恩&结肠炎基金会的成员将加强我们与该基金会、FDA和其他制药公司在开发IBD精准治疗方面的合作。我们很荣幸成为CCF企业圈子的一员。” “克罗恩&结肠炎基金会代表着致力于寻找克罗恩病和溃疡性结肠炎治疗方法的首屈一指的非营利组织,”阿托斯董事长兼首席医疗官、医学博士艾伦·J·潘塔克说。“我们期待着支持它的使命,并与克罗恩和结肠炎基金会密切合作,帮助寻找新的治疗方法,提高受这些疾病影响的人的生活质量。” 克罗恩&结肠炎基金会负责业务发展的高级副总裁约翰·米泽补充说:“该基金会致力于为IBD寻找新的更好的治疗方法,并提高患者的生活质量。我们感谢Athos支持我们的使命,并感谢Athos对IBD社区的影响。” 关于Athos疗法 Athos Therapeutics Inc.是一家晚期临床前生物技术公司,使用高度创新的化学和计算过程开发小分子治疗自身免疫性疾病。Athos的联合创始人包括Kite Pharma(以12B美元收购)的联合创始人,两种数十亿美元FDA批准药物(Xtandi和Erleada)背后的药物化学家,以及目前正在进行第三期IBD试验的miR-124药物靶点的发现者。Athos通过将临床和分子数据集整合到疾病间期来识别新的药物靶点(中枢),并将它们匹配到其小分子计算化学平台。该公司的主导药物化合物ATH-63正在进入溃疡性结肠炎和克罗恩病患者的Ia期人体临床试验Q12022。管道项目包括狼疮和多种癌症。 关于克罗恩和结肠炎基金会 克罗恩&结肠炎基金会是主要的非营利组织,专注于炎症性肠病(IBD)的研究和患者支持。该基金会的使命是治愈克罗恩病和溃疡性结肠炎,并改善数百万患有IBD的美国人的生活质量。我们的工作正在极大地加速研究进程;我们还为患者及其家属、医疗专业人员和公众提供广泛的教育资源。欲了解更多信息,请访问http://www.crohnscolitisfoundation.org,致电888-694-8872,或发电子邮件info@crohnscolitisfoundation.org。 多媒体:https://www.prnewswire.com/news-releases/athos-therapeutics-announces-their-corporate-circle-membership-to-the-crohns-colitis-foundation-and-participation-in-the-ibd-innovate-conference-301399394.html

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文